Randomized Trialhigh evidence
Efficacy and Safety of Ulinastatin in the Treatment of Patients with Sepsis: The ADJUST Trial.
Chest·November 6, 2026·PMID 42994751
Why it mattersSepsis remains a leading cause of ICU mortality, and prior observational data suggested ulinastatin might improve survival. This adequately powered RCT provides high-level evidence that adjunctive ulinastatin does not reduce mortality and may increase adverse events, informing critical care and internal medicine practice.

The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled